Insmed Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Insmed press release (INSM): Q4 GAAP EPS of -$0.95 misses by $0.05.Revenue of $56.12M (+35.5% Y/Y) beats by $5.28M.The company expects full-year 2022 revenues for ARIKAYCE to…

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…

Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BRIDGEWATER, N.J., Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the SVB Leerink Virtual 11th Annual

Credit Suisse argues that BioMarin Pharmaceutical <>, United Therapeutics <>, and Insmed Incorporated <> still carry further upside opportunities in 2022, despite…

Eleison Pharmaceuticals acquires, develops and commercializes late-stage therapies for orphan diseases with unmet needs. The Company's three pipeline candidates have received the Orphan Drug Designati

Brokerages expect that Insmed Incorporated (NASDAQ:INSM) will report sales of $51.26 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Insmeds earnings, with the lowest sales estimate coming in at $49.14 million and the highest estimate coming in at $53.77 million. Insmed posted sales of $41.42 million during the []

WCM Investment Management LLC lifted its stake in Insmed Incorporated (NASDAQ:INSM) by 41.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 225,815 shares of the biopharmaceutical companys stock after purchasing an additional 66,316 shares during the quarter. WCM Investment Management LLCs holdings []

Parametric Portfolio Associates LLC cut its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,797 shares of the biopharmaceutical companys stock after selling 2,928 shares during the quarter. Parametric Portfolio Associates LLCs []

JPMorgan Chase & Co. started coverage on shares of Insmed (NASDAQ:INSM) in a research note released on Monday morning, Analyst Ratings Network reports. The firm issued an overweight rating and a $45.00 target price on the biopharmaceutical companys stock. Several other analysts have also weighed in on INSM. Zacks Investment Research upgraded shares of Insmed []

Wall Street analysts expect Insmed Incorporated (NASDAQ:INSM) to announce sales of $51.26 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Insmeds earnings, with the lowest sales estimate coming in at $49.14 million and the highest estimate coming in at $53.77 million. Insmed reported sales of $41.42 []